Concepedia

Cost‐Effectiveness Analysis of HLA–B5801 Genotyping in the Treatment of Gout Patients With Chronic Renal Insufficiency in Korea

Dong‐Jin Park, Ji‐Hyoun Kang, Jeong‐Won Lee, Kyung‐Eun Lee, Lihui Wen, Tae‐Jong Kim, Yong‐Wook Park, Sung‐Hwan Park, Shin‐Seok Lee

Arthritis Care & Research · 2014 · 64 citations · 29 references

DOI

Abstract

Our model suggests that gout treatment informed by HLA-B5801 genotyping is less costly and more effective than treatment without genotyping, and HLA-B5801 genotyping could considerably reduce the occurrence of allopurinol-induced SCARs and related deaths.

References

29

A marker for Stevens–Johnson syndrome

Wen‐Hung Chung, Hong‐Shang Hong, Mo‐Song Hsih et al. · Nature · 2004 · 1.7K citations · Full text

, , +7

2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

Dinesh Khanna, John FitzGerald, Puja Khanna et al. · Arthritis Care & Research · 2012 · 1.5K citations · Full text

, , +17

Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis

Jean‐Claude Roujeau, Judith P. Kelly, Luigi Naldi et al. · New England Journal of Medicine · 1995 · 1.4K citations

Association between presence of HLA-B*5701, HLA-DR7 , and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

S. Mallal, David Nolan, Campbell S. Witt et al. · The Lancet · 2002 · 1.4K citations

, , +7

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

Wen‐Hung Chung, Lieh-Bang Liou, C.C. Chu et al. · Proceedings of the National Academy of Sciences · 2005 · 1.3K citations · Full text